NATCO PHARMA
Quarterly Results Analysis [Mar2025]
NATCO PHARMA Quarterly Results
Consolidated | Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,221 Cr | ₹475 Cr | ₹1,371 Cr | ₹1,363 Cr | ₹1,068 Cr | ₹759 Cr | ₹1,031 Cr | ₹1,141 Cr |
Expenses | ₹673 Cr | ₹436 Cr | ₹567 Cr | ₹558 Cr | ₹571 Cr | ₹491 Cr | ₹573 Cr | ₹613 Cr |
Operating Income | ₹548 Cr | ₹39 Cr | ₹804 Cr | ₹805 Cr | ₹497 Cr | ₹268 Cr | ₹458 Cr | ₹528 Cr |
Other Income | ₹66 Cr | ₹176 Cr | ₹64 Cr | ₹48 Cr | ₹42 Cr | ₹37 Cr | ₹29 Cr | ₹20 Cr |
Interest | ₹10 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr |
Depreciation | ₹98 Cr | ₹47 Cr | ₹46 Cr | ₹44 Cr | ₹56 Cr | ₹44 Cr | ₹44 Cr | ₹44 Cr |
Profit Before Tax | ₹506 Cr | ₹164 Cr | ₹818 Cr | ₹804 Cr | ₹478 Cr | ₹256 Cr | ₹440 Cr | ₹500 Cr |
Profit After Tax | ₹406 Cr | ₹132 Cr | ₹677 Cr | ₹669 Cr | ₹386 Cr | ₹213 Cr | ₹369 Cr | ₹420 Cr |
EPS | ₹22.72 | ₹7.43 | ₹37.84 | ₹37.35 | ₹21.58 | ₹11.88 | ₹20.61 | ₹23.48 |
Industry Peers & Returns | 1W | 1M | 1Y |
NATCO PHARMA | 5.7% | 10.8% | -15.8% |
SUN PHARMACEUTICAL INDUSTRIES | -0.3% | -2.9% | 11.5% |
DIVIS LABORATORIES | 0.7% | 7.4% | 48.1% |
CIPLA | -0.1% | 0.2% | -2.1% |
TORRENT PHARMACEUTICALS | 2.3% | -0.5% | 13.8% |
DR REDDYS LABORATORIES | 3.2% | 10.3% | 11.7% |
MANKIND PHARMA | 1.1% | -7% | 9.7% |
ZYDUS LIFESCIENCES | 0.2% | 7.8% | -9.8% |
LUPIN | 0.3% | -3.4% | 23.6% |
NATCO PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 157.16 % |
Y-o-Y | 14.29 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹1,221 Cr | 157.16 | |
Dec2024 | ₹475 Cr | -65.37 | |
Sep2024 | ₹1,371 Cr | 0.62 | |
Jun2024 | ₹1,363 Cr | 27.55 | |
Mar2024 | ₹1,068 Cr | 40.83 | |
Dec2023 | ₹759 Cr | -26.45 | |
Sep2023 | ₹1,031 Cr | -9.57 | |
Jun2023 | ₹1,141 Cr | - |
NATCO PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 1,312.63 % |
Y-o-Y | 10.22 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹548 Cr | 1,312.63 | |
Dec2024 | ₹39 Cr | -95.18 | |
Sep2024 | ₹804 Cr | -0.06 | |
Jun2024 | ₹805 Cr | 61.83 | |
Mar2024 | ₹497 Cr | 85.49 | |
Dec2023 | ₹268 Cr | -41.46 | |
Sep2023 | ₹458 Cr | -13.26 | |
Jun2023 | ₹528 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 449.45 % |
Y-o-Y | -3.57 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 44.89% | 449.45 | |
Dec2024 | 8.17% | -86.07 | |
Sep2024 | 58.66% | -0.68 | |
Jun2024 | 59.06% | 26.87 | |
Mar2024 | 46.55% | 31.72 | |
Dec2023 | 35.34% | -20.42 | |
Sep2023 | 44.41% | -4.08 | |
Jun2023 | 46.3% | - |
NATCO PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 206.65 % |
Y-o-Y | 5.10 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹406 Cr | 206.65 | |
Dec2024 | ₹132 Cr | -80.43 | |
Sep2024 | ₹677 Cr | 1.20 | |
Jun2024 | ₹669 Cr | 73.05 | |
Mar2024 | ₹386 Cr | 81.62 | |
Dec2023 | ₹213 Cr | -42.36 | |
Sep2023 | ₹369 Cr | -12.21 | |
Jun2023 | ₹420 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 19.22 % |
Y-o-Y | -8.05 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 33.25 % | 19.22 | |
Dec2024 | 27.89 % | -43.47 | |
Sep2024 | 49.34 % | 0.57 | |
Jun2024 | 49.06 % | 35.67 | |
Mar2024 | 36.16 % | 28.96 | |
Dec2023 | 28.04 % | -21.63 | |
Sep2023 | 35.78 % | -2.90 | |
Jun2023 | 36.85 % | - |
NATCO PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 205.79 % |
Y-o-Y | 5.28 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹22.72 | 205.79 | |
Dec2024 | ₹7.43 | -80.36 | |
Sep2024 | ₹37.84 | 1.31 | |
Jun2024 | ₹37.35 | 73.08 | |
Mar2024 | ₹21.58 | 81.65 | |
Dec2023 | ₹11.88 | -42.36 | |
Sep2023 | ₹20.61 | -12.22 | |
Jun2023 | ₹23.48 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD